# US 8,569,017 B2 · Method for the preventing and/or treating IL-1 beta lung pathology in mammals by administering a uric acid reducing compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,017 B2
- Document ID: US8569017B2
- Status: Granted
- Kind: B2
- Application number: 13/119,363
- Filed: 2009-09-18
- Published: 2011-10-06
- Granted: 2013-10-29
- Earliest claimed: 2008-09-18
- Assignees: Centre National de la Recheche Scientifique (CNRS)
- Applicants: Bernhard Ryffel; Isabelle Couillin
- Inventors: Bernhard Ryffel; Isabelle Couillin
- Web page: https://patentgrep.com/patent/US8569017B2

## CPC

- A61K 38/44: Oxidoreductases (1)
- A61K 31/195: having an amino group
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/4152: having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61K 31/77: of oxiranes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- C12Q 1/62: involving uric acid
- C12Y 107/03003: Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- Y10T 436/148888: Uric acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention is directed to the use of a compound capable of reducing the uric acid level in a mammal for the prevention and/or the treatment of IL-Iβ driven lung pathology, particularly to treat lung inflammation such as chronic fibrosis, COPD and interstitial fibrosis and other IL-1β driven lung pathologies including those of autoimmune origin. Preferred compounds capable of reducing the uric acid level are selected from the group consisting of xanthine oxidase inhibitors, such as allopurinol, recombinant enzyme uricase and uricosuric compound capable of enhancing uric acid excretion, such as probenecid. The invention further relates to a method for identifying in vitro whether a patient presents an IL-1β driven lung pathology or is at risk to develop an IL-1β driven lung pathology, or for the screening of a compound for treating an IL-1β driven lung pathology.

## Claims

### Claim 1

A method for the prevention and/or the treatment of IL-1β driven lung pathology in a mammal in need thereof, comprising the step of administering an effective amount of a compound capable of reducing the uric acid level in said mammal, wherein said compound is selected from the group consisting of:
an uricase, a recombinant uricase, and a functional fragment thereof, and
an uricosuric compound, an inhibitor of the tubular organic anion transporter resulting in the augmentation of renal elimination of uric acid, and a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A method according to claim 1, wherein said IL-1β driven lung pathology is selected from the group consisting of lung inflammation, lung fibrosis and lung pathologies from autoimmune origin.

### Claim 3 (depends on 1)

A method according to claim 1, wherein said IL-1β driven lung pathology is a lung inflammation leading to fibrosis and respiratory failure.

### Claim 4 (depends on 1)

A method according to claim 1, wherein said recombinant uricase is rasburicase.

### Claim 5 (depends on 4)

A method according to claim 4, wherein said uricase is pegylated.

### Claim 6 (depends on 1)

A method according to claim 1, wherein said uricosuric compound or inhibitor of the tubular organic anion transporter resulting in the augmentation of renal elimination of uric acid is selected from the group consisting of probenecid, benzbromarone, sulfinpyrazone, thromboxane synthetase inhibitors and thromboxane receptor antagonists.

### Claim 7 (depends on 1)

A method according to claim 1, wherein said composition is administered by intravenous injection, by intramuscular injection or orally.

### Claim 8 (depends on 2)

A method according to claim 2, wherein lung fibrosis is selected from the group consisting of chronic fibrosis, chronic obstructive pulmonary disease (COPD) and interstitial fibrosis.